ClinicalTrials.gg
CompletedNCT03882905Updated May 10, 2024

A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)

A Phase 3 interventional study of Ezetimibe and Placebo in Primary Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2001, 25 years 3 months ago, and no results have been posted to the registry.
  • Registered 18 years 1 month after the study started (first participant enrolled Jan 2001, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
9th of 97
769 · median 148
Started
2001
with 1 other
Phase 3
50 of 98
1 open now
Registered
85th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 9th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2001, is one of 50 in phase 3, and was the 85th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants with primary hypercholesterolemia, multiple cardiovascular risk factors, or known coronary heart disease (CHD) or CHD-equivalent disease. The statin and dose in use by the participant at screening will be maintained at the same dose for the 8-week treatment phase of the study. Following the treatment, there will be a 6-week cholesterol reversibility phase to determine the rebound effect on cholesterol after ezetimibe is discontinued, but the participant is still on their statin therapy. The primary hypothesis is that the addition of ezetimibe 10 mg/day to ongoing statin monotherapy will result in a further reduction in low-density lipoprotein-cholesterol (LDL-C) compared with placebo.

The protocol was amended to include an extension for participants who complete the base study. The extension will evaluate the safety and tolerability of concomitant treatment of simvastatin with ezetimibe10 mg/day over a 1-year period. All participants in the extension will be converted from current statin to an equivalent dose of simvastatin for 6 weeks. Participants then will be randomly assigned to receive simvastatin coadministered with either with Ezetimibe 10 mg daily or matching placebo for the reminder of study.

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Currently taking an approved and stable (for at least 6 weeks prior to screening) daily dose of a statin and by history had taken >80% of daily doses for the preceding 6 weeks
  • Have a negative pregnancy test
  • Agree to practice an effective barrier method of during the study if of
  • Females receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral contraceptives, maintain a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the duration of the study
  • Must verify previous instruction on an National Cholesterol Education Program (NCEP) Step 1 diet or similar diet and must maintain a stable diet regimen for the duration of the study
  • Weight stability ( ± 2 kg) for at least 6 weeks prior to entry into the study Exclusion Criteria
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Previously enrolled to any study evaluating ezetimibe
  • Pregnant or lactating
  • Consumes greater than 14 alcoholic drinks/week
  • Taking a lipid-altering agent (other than statins) in previous 6 weeks
  • Taking Oral , unless the corticosteroids were for replacement therapy to treat pituitary/adrenal disease and were treated with a stable regimen for at least the previous 6 weeks
  • Treatment with psyllium, other fiber-based laxatives, and other over-the-counter (OTC) therapies that affect serum lipids, unless treated with a stable regimen for at least 6 weeks
  • Taking orlistat
  • Taking cyclosporine
  • Use of any drugs within 30 days
  • Treatment with agents with known interactions with statins including antifungal azoles (itraconazole and ketoconazole), macrolide antibiotics (erythromycin and clarithromycin) and nefazodone or with other potent agents that could significantly interfere with cytochrome P-450 system
  • Congestive heart failure (NYHA) Class III or IV
  • Uncontrolled cardiac arrhythmias
  • Myocardial infarction, coronary artery bypass surgery or angioplasty within 3 months
  • Unstable or severe peripheral artery disease within 3 months
  • Unstable angina pectoris
  • Disorders of the hematologic, digestive or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation
  • Poorly controlled or newly diagnosed (within 3 months) diabetes mellitus, or change in antidiabetic pharmacotherapy (i.e., change in dosage [with the exception of ± 10 units of insulin] or addition of new medication) within 3 months
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e., secondary causes of hyperlipidemia). Clinically euthyroid participants on replacement doses of thyroid hormone are eligible for enrollment if thyroid stimulating hormone (TSH) is within the normal range
  • Impaired renal function, nephrotic syndrome, or other renal disease
  • Active or chronic hepatobiliary or hepatic disease
  • Positive for (HIV)
  • Cancer within the past 5 years (except for basal cell carcinoma)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
769 participants (actual)

Study arms

  • Experimental
    Ezetimibe: Base Study

    10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.

    Drug: Ezetimibe · Drug: Statin

  • Placebo comparator
    Placebo: Base Study

    Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.

    Drug: Placebo · Drug: Statin

  • Experimental
    Ezetimibe: Extension

    10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.

    Drug: Ezetimibe · Drug: Simivastatin

  • Placebo comparator
    Placebo: Extension

    Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.

    Drug: Placebo · Drug: Simivastatin

Interventions

  • 10 mg tablet, oral, once daily

  • DrugPlacebo

    one tablet, oral, once daily

  • DrugSimivastatin

    Once daily administration at dose to be determined

  • DrugStatin

    Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician

06

What researchers measure

Primary outcomes

  1. Percentage Change from Baseline in LDL-C: Base Study

    Time frame: Baseline and Week 8 of Base Study

  2. Percentage Participants with Consecutive Elevations ≥3 x Upper Limit of Normal (ULN) in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT): Extension

    Time frame: up to 48 weeks (Extension)

Secondary outcomes

  1. Percentage of Participants Achieving LDL-C National Cholesterol Education Program (NCEP) Adult Treatment Program II (ATP II) Target Levels: Base Study

    Time frame: Week 8 of Base Study

  2. Percentage Change from Baseline in Total Cholesterol (TC) : Base Study

    Time frame: Baseline and Week 8 of Base Study

  3. Percentage Change from Baseline in Triglycerides (TG): Base Study

    Time frame: Baseline and Week 8 of Base Study

  4. Percentage Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C) : Base Study

    Time frame: Baseline and Week 8 of Base Study

  5. Percentage Change from Baseline in Non-HDL-C: Base Study

    Time frame: Baseline and Week 8 of Base Study

  6. Percentage Change from Baseline in Apolipoprotein B (apoB) : Base Study

    Time frame: Baseline and Week 8 of Base Study

  7. Percentage Change from Baseline in Apolipoprotein A-I (Apo A-I) : Base Study

    Time frame: Baseline and Week 8 of Base Study

  8. Percentage Change from Baseline in Apolipoprotein A-II (Apo A-II) : Base Study

    Time frame: Baseline and Week 8 of Base Study

  9. Percentage Change from Baseline in LDL-C:HDL-C Ratio: Base Study

    Time frame: Baseline and Week 8 of Base Study

  10. Percentage Change from Baseline in Total-C:HDL-C Ratio: Base Study

    Time frame: Baseline and Week 8 of Base Study

  11. Change from Baseline in C-reactive Protein (CRP): Base Study

    Time frame: Baseline and Week 8 of Base Study

  12. Percentage Change from Baseline in LDL-C: Extension

    Time frame: Baseline (Week 6) and Week 18 of Extension

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Masana L, Mata P, Gagne C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B; Ezetimibe Study Group. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther. 2005 Feb;27(2):174-84. doi: 10.1016/j.clinthera.2005.02.011. PubMed 15811480 ↗
  • Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002 Nov 15;90(10):1084-91. doi: 10.1016/s0002-9149(02)02774-1. PubMed 12423708 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2001 to primary completion in Jul 2001, 5 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 20, 2019
StartActual
Jan 31, 2001
Primary completionActual
Jul 27, 2001
CompletionActual
Jul 27, 2001
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03882905
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 20, 2019
Start date
Jan 31, 2001
Primary completion
Jul 27, 2001
Completion
Jul 27, 2001
Last update
May 10, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Statins

Start the discussion